You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
墨西哥就中国研发mRNA新冠疫苗进行第三阶段临床测试
阿思达克 05-12 11:52
《路透》报道,墨西哥外长Marcelo Ebrard表示,当地计划就中国云南沃森生物研发,采用信使核糖核酸(mRNA)技术的新冠疫苗进行第三阶段临床测试。测试将於5月30日开始,6,000名志愿者参与。

该疫苗与中国人民解放军军事科学院及苏州艾博生物科技共同研发,使用技术与辉瑞(PFE.US)及Moderna(MRNA.US)相似,为中国首款mRNA技术新冠疫苗进入第三阶段临床测试。疫苗可於摄氏2至8度环境下储存。

墨西哥目前已接收中国科兴(SVA.US)及康希诺生物(06185.HK)疫苗,并计划订购中国国药疫苗。中国本土目前使用5款自家研发的疫苗,当中未有使用mRNA技术。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account